Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06495658 · ClinicalTrials.gov registry record · NA

Impact of Prebiotics in Ulcerative Colitis

A NA study of Ulcerative Colitis and Crohn Disease, sponsored by University of California, Los Angeles.

Recruiting
Registry status
NA
Development phase
70
Enrollment target
1
Study location

NCT06495658: Recruiting NA study of Ulcerative Colitis and Crohn Disease, sponsored by University of California, Los Angeles.

NCT06495658 is a NA study of Ulcerative Colitis and Crohn Disease that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 70 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06495658, a NA study of Ulcerative Colitis and Crohn Disease, is actively recruiting participants, sponsored by University of California, Los Angeles.

RECRUITING
Registry status
NA
Development phase
70 participants
Enrollment target
1
Study location

Study Summary

The cause of inflammatory bowel disease (IBD) is currently unknown, although partly attributed to interactions among genetic risk polymorphisms, environmental factors, gut microbiome, and host immunity. Diet, particularly those with plant-based products, have been shown in prior research to improve gut microbial composition, which has been linked to different IBD-related outcomes. This study is interested in evaluating the impact of prebiotics on gut microbiome composition and gut health in patients with IBD. Dietary composition will be assessed at baseline and over the course of 16 weeks. Participants will be randomized to either consume an 8-week course of prebiotic supplementation beginning at week 0 or week 8. Stool samples will be collected at weeks 0 and 8. The stool will be analyzed for cross-sectional and longitudinal fecal microbial changes associated with different prebiotic and diet consumption patterns in the context of heterogeneous disease characteristics.

Primary Outcome

Clinical remission will be defined as a Simple Colitis Clinical Activity Index (SCCAI) \< 4. Range of SCCAI is 0-20 (higher is more severe).

Conditions Studied

Ulcerative Colitis Crohn Disease

Interventions

  • DIETARY_SUPPLEMENT Prebiotic

Study Locations (1)

California

  • UCLA - Los Angeles

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2024-07-09
Est. Completion 2027-12-31
Phase NA
University of California, Los Angeles

897 total trials

What NCT06495658 shows while recruiting

NCT06495658 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (97% lower).

The record links to 2 conditions, with Ulcerative Colitis appearing as the primary indexed condition, and to 1 intervention - of which Prebiotic is the first listed.

NCT06495658 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06495658 about?

NCT06495658 is a clinical study titled "Impact of Prebiotics in Ulcerative Colitis". The cause of inflammatory bowel disease (IBD) is currently unknown, although partly attributed to interactions among genetic risk polymorphisms, environmental factors, gut microbiome, and host immunity. Diet, particularly those with plant-based products, have been shown in prior research to improve ...

What is the current status of trial NCT06495658?

This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2024-07-09. Estimated completion is 2027-12-31.

What conditions does trial NCT06495658 study?

This clinical trial studies the following conditions: Ulcerative Colitis, Crohn Disease.

What interventions are being tested in trial NCT06495658?

The interventions under investigation include: Prebiotic (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06495658?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06495658 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ulcerative Colitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06495658's enrollment target sits among peer trials

70 72nd of 122 higher than 49 of 122 other Ulcerative Colitis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00969111 · 70 participants · NA

    Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

  • NCT01712620 · 70 participants · Phase 2

    Spironolactone for Pulmonary Arterial Hypertension

  • NCT02143830 · 70 participants · Phase 2

    HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

  • NCT02601339 · 70 participants

    NIRS Monitoring in Premature Infants

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06495658

Source: ClinicalTrials.gov NCT06495658, the US trial registry maintained by the National Library of Medicine. NCT06495658 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.